Abbott Laboratories $ABT Stock Sold by Stokes Capital Advisors LLC

Key Points

• Stokes Capital Advisors reduced its Abbott Laboratories stake by 30.9% in the third quarter, selling 13,878 shares and retaining 31,056 shares valued at approximately $3.07 million.
• Analysts remain broadly positive, with Abbott holding a consensus “Moderate Buy” rating and an average price target of $118.88; several firms recently raised their targets or upgraded the stock.
• Abbott reported quarterly revenue of $12.59 billion and EPS of $1.31, exceeding estimates, while declaring a quarterly dividend of $0.63 per share—an annualized yield of about 2.5%.

Stokes Capital Advisors LLC lessened its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 30.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 31,056 shares of the healthcare product maker's stock after selling 13,878 shares during the quarter. Stokes Capital Advisors LLC's holdings in Abbott Laboratories were worth $3,069,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories during the 4th quarter worth $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth about $26,000. Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Prudent Man Investment Management Inc. bought a new position in Abbott Laboratories in the 4th quarter valued at approximately $33,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several analyst reports. Piper Sandler reissued an "overweight" rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Weiss Ratings raised Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, September 18th. JPMorgan Chase & Co. increased their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. BTIG Research raised their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a research report on Friday, July 17th. Finally, Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price on the stock in a report on Thursday, August 13th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of "Moderate Buy" and an average target price of $118.88.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $99.71 on Friday. The business has a 50-day simple moving average of $106.25 and a 200 day simple moving average of $98.35. Abbott Laboratories has a one year low of $81.97 and a one year high of $134.50. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a market capitalization of $172.53 billion, a price-to-earnings ratio of 32.27, a PEG ratio of 1.83 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. During the same period last year, the company earned $1.26 earnings per share. The business's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.5%. Abbott Laboratories's dividend payout ratio is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories NYSE: ABT is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott's medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.